Clinical Study Safety and Efficacy of Tablet Extract Compared to Hyperuricemia Herbs Aqueous Extract
DOI:
https://doi.org/10.35814/jifi.v19i1.739Keywords:
clinical study, tablet and aqueous extract, hyperuricemia herbsAbstract
Hyperuricemia is a metabolic disorder that is often found in the community, and requires long-term
treatment. To determine the effi cacy and safety of the hyperuricemia herbs, clinical studies have been carried out on the effi cacy and safety of tablet preparations compared to boiled of the hyperuricemia herbs. The clinical study was conducted with an open label research design, randomized clinical study and parallel design. The study involved 55 subjects who had met the inclusion and exclusion criteria. Subjects were randomized and divided into groups of tablets or boiled with intervention for 28 days. The tablet group took tablets with a dose of 3x2 tablets per day and the boiled group drank infusion with a dose of 3 times a glass per day. Blood uric acid was examined at D0, D14 and D28. SGOT, SGPT, urea, and creatinine were examined at D0 and D28. The tablet reduced uric acid (7.74 mg/dL to 6.53 mg/dL) and the boiled reduced uric acid (7.93 mg/dL to 7.09 mg/dL). The administration of tablet preparations eliminates the clinical symptoms of swollen/pain of leg, swollen/pain of hand, stiff ness, pain and other symptoms at the deff erent time than boiled administration. The administration of both preparations for 28 days in the subjects did not increase the value of SGOT, SGPT, urea and creatinine and no symptoms of serious side eff ects were found.
References
Downloads
Published
Issue
Section
License
Licencing
All articles in Jurnal Ilmu Kefarmasian Indonesia are an open-access article, distributed under the terms of the Creative Commons Attribution-NonCommercial-ShareAlike 4.0 International License which permits unrestricted non-commercial used, distribution and reproduction in any medium.
This licence applies to Author(s) and Public Reader means that the users mays :
- SHARE:
copy and redistribute the article in any medium or format - ADAPT:
remix, transform, and build upon the article (eg.: to produce a new research work and, possibly, a new publication) - ALIKE:
If you remix, transform, or build upon the article, you must distribute your contributions under the same license as the original. - NO ADDITIONAL RESTRICTIONS:
You may not apply legal terms or technological measures that legally restrict others from doing anything the license permits.
It does however mean that when you use it you must:
- ATTRIBUTION: You must give appropriate credit to both the Author(s) and the journal, provide a link to the license, and indicate if changes were made. You may do so in any reasonable manner, but not in any way that suggests the licensor endorses you or your use.
You may not:
- NONCOMMERCIAL: You may not use the article for commercial purposes.
This work is licensed under a Creative Commons Attribution-NonCommercial-ShareAlike 4.0 International License.

















